The use of injectable Chitosan/Nanohydroxyapatite/collagen composites with bone marrow mesenchymal stem cells to promote ectopic bone formation in vivo
The use of injectable Chitosan/Nanohydroxyapatite/collagen composites with bone marrow mesenchymal stem cells to promote ectopic bone formation in vivo
复制标题
DOI：
10.1155/2013/506593
复制
发表时间：
2013
影响因子：
--
通讯作者：
Bo Yu;Yichen Zhang;Xiaoming Li;Qiongren Wang;Y. Ouyang;Yuan-sheng Xia;Bomiao Lin;Songjian Li
中科院分区：
文献类型：
--
作者：
Bo Yu;Yichen Zhang;Xiaoming Li;Qiongren Wang;Y. Ouyang;Yuan-sheng Xia;Bomiao Lin;Songjian Li
本研究的目的是评估有或没有大鼠骨髓间充质干细胞（rBMSCs）的可注射壳聚糖/纳米羟基磷灰石/胶原（CS/nHAC）复合材料的异位体内骨形成。将CS/nHAC复合材料以10 × 106 cells/mL的密度接种于Wistar大鼠背部皮下，以不含细胞的CS/nHAC复合材料作为阴性对照。通过计算机断层扫描（CT）和三维（3D）CT重建评价新骨形成、复合材料降解和钙化程度。通过HE和Masson染色进行组织学评价以进一步评估骨结构和细胞外基质。本研究还探讨了与成骨相关的炎症反应。与CS/nHAC复合材料相比，CS/nHAC/rBMSCs复合材料具有较高的钙化率、较好的ECM形成和较低的降解率。同时，CS/nHAC和CS/nHAC/rBMSCs植块在植入后2周和4周均出现不同程度的炎症反应。CS/nHAC/rBMSCs复合材料异位成骨能力上级优于CS/nHAC复合材料。结论：rBMSCs种植CS/nHAC复合材料有利于促进异位成骨。
The aim of this study was to evaluate ectopic in vivo bone formation with or without rat bone mesenchymal stem cells (rBMSCs) of an injectable Chitosan/Nanohydroxyapatite/Collagen (CS/nHAC) composite. The CS/nHAC composites were injected subcutaneously into the backs of Wistar rats with freshly loaded rBMSCs at a density of 10 × 106 cells/mL, and the CS/nHAC composites without cellswere used as negative controls. Newbone formation, degradation of composites, and degree of calcification were evaluated by Computed Tomography (CT) and three-dimensional (3D) CT reconstruction. Histological evaluations were performed to further assess bone structure and extracellular matrix by HE and Masson staining. The inflammatory reactions related to osteogenesis were also investigated in the present study. In comparison with the CS/nHAC composites, this study revealed that CS/nHAC/rBMSCs composites showed relatively higher percentage of calcification, better establishment of ECM, and less degradation rate. Meanwhile, different extents of inflammatory reactions were also observed in the CS/nHAC and CS/nHAC/rBMSCs explants at 2 and 4 weeks after implantation. Altogether, CS/nHAC/rBMSCs composites are superior to CS/nHAC composites in ectopic bone formation. In conclusion, the rBMSCs-seeded CS/nHAC composites may be beneficial to enhancing ectopic bone formation in vivo.